Researchers have hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them, but only if the right second agent is used.
Many tumours do not respond to drugs, and even those that do often develop resistance over time.
Thyroid Cancer
"Shaped like a butterfly she sits within the neck," that's what an anonymous poet wrote about the thyroid gland but it can become cancerous and spread to other parts.
Advertisement
And in a bid to combat this problem of resistance, researchers at Fox Chase Cancer Center made the above hypothesis.
One well-validated molecular target for anti-cancer drugs is the epidermal growth factor receptor, or EGFR. Using a novel screening approach, investigators in the Fox Chase Developmental Therapeutics Program identified over 60 additional proteins that are necessary for cells to survive in the presence of an EGFR inhibitor.
![Bladder Cancer]( "Bladder Cancer")
Bladder Cancer affects the urinary bladder and can be superficial or deep type and this affects its recurrence rate & prognosis.
When they simultaneously blocked the EGFR inhibitors and any one of these other proteins, more of the cancer cells died.
The researchers said that this screening strategy to identify targets for effective combinations of cancer drugs will open the door for future therapies.
Already, two clinical trials are under way to test innovative drug combinations suggested by the new tactic.
"We found that knocking out one or the other target doesn't have a major effect, but knocking out both increases tumor cell death," said Dr. Igor Astsaturov, who led the study.
To identify additional targets that would boost the effectiveness of EGFR inhibitors against cancer, the researchers screened only proteins that interact directly or indirectly with EGFR.
The team mined the literature and built a candidate set of 638 EGFR-interacting proteins.
They then used an experimental technique called small inhibitory RNA (siRNA) systematically to block activity of each of the genes in cancer cells that had been treated with an EGFR inhibitor.
In doing so, the investigators demonstrated on three clinically relevant examples for which drugs are already available-PRKC, STAT3, and Aurora kinase A-that these proteins were necessary for cell survival in the presence of an EGFR inhibitor.
This two-hit strategy-where neither hit is adequate to kill the cells, but together they are-is called synthetic lethality.
The study is published in the latest issue of Science Signaling.
Source: ANI
Bladder Cancer
Bladder Cancer affects the urinary bladder and can be superficial or deep type and this affects its recurrence rate & prognosis.
Advertisement
When they simultaneously blocked the EGFR inhibitors and any one of these other proteins, more of the cancer cells died.
The researchers said that this screening strategy to identify targets for effective combinations of cancer drugs will open the door for future therapies.
Already, two clinical trials are under way to test innovative drug combinations suggested by the new tactic.
"We found that knocking out one or the other target doesn't have a major effect, but knocking out both increases tumor cell death," said Dr. Igor Astsaturov, who led the study.
To identify additional targets that would boost the effectiveness of EGFR inhibitors against cancer, the researchers screened only proteins that interact directly or indirectly with EGFR.
The team mined the literature and built a candidate set of 638 EGFR-interacting proteins.
They then used an experimental technique called small inhibitory RNA (siRNA) systematically to block activity of each of the genes in cancer cells that had been treated with an EGFR inhibitor.
In doing so, the investigators demonstrated on three clinically relevant examples for which drugs are already available-PRKC, STAT3, and Aurora kinase A-that these proteins were necessary for cell survival in the presence of an EGFR inhibitor.
This two-hit strategy-where neither hit is adequate to kill the cells, but together they are-is called synthetic lethality.
The study is published in the latest issue of Science Signaling.
Source: ANI
Tumor Markers For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive results.
Advertisement
 Uterine CancerUterine Cancer or Cancer of the Uterus (or Endometrial Cancer) refer to cancers affecting the uterus or the womb in women. Learn about the different types of uterine cancer, symptoms, staging, diagnosis, prognosis, treatment, survival rates and news on uterine cancer. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
A ray of hope for glioma patients as targeted therapy boosts treatment duration.